Wow! eBook
Pharmaceutical Innovation, Competition and Patent Law: A Trilateral Perspective
Author(s): Josef Drexl (Editor), Nari Lee
- Publisher: Edward Elgar Publishing Ltd
- Publication Date: 30 July 2013
- Edition: First Edition
- Language: English
- Print length: 352 pages
- ISBN-10: 0857932454
- ISBN-13: 9780857932457
Book Description
Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicine and health care.
Addressing fundamental questions in the field of pharmaceutical innovation, this book will appeal to scholars and practitioners in intellectual property, competition law and life sciences regulation, as well as pharmaceutical companies and regulators.
Contributors: R. Arnold, M.A. Bagley, B. Domeij, J. Drexl, R.C. Dreyfuss, C.R. Fackelmann, T. Imura, R. Iseki, N. Lee, R. Moufang, H. Ullrich
Editorial Reviews
Review
–Marcus Norrgard, International Review of Intellectual Property and Competition Law
‘This is an intriguing selection of topical essays addressing fundamental questions of pharmaceutical innovation. It is comprised of a high-profile list of contributors, including academics, judges and practitioners from the U.S., Europe and Japan, who ”explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicines and health care”. . . This is an enjoyable, readable and interesting book containing thorough studies of ”hot” legal issues in the pharma sector converging in an decisive era for pharmaceutical innovation. It ought to be found in any library that has reserved space for pharma-, IP- or competition law-related literature.’
–Jur. Dr. Timo Minssen, European Competition Law Review
